Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platelet Integrin αIIbβ3 Activation is Associated with 25-Hydroxyvitamin D Concentrations in Healthy Adults.

Thrombosis and haemostasis·2020
Same author

The COPDnet integrated care model.

International journal of chronic obstructive pulmonary disease·2018
Same author

Evaluation of the COPDnet integrated care model in patients with COPD: the study protocol.

International journal of chronic obstructive pulmonary disease·2018
Same author

Microbiological and immunological characteristics of a lethal pulmonary <i>Aspergillus niger</i> infection in a non-neutropenic patient.

Medical mycology case reports·2018
Same author

Randomised controlled trial of adjunctive inspiratory muscle training for patients with COPD.

Thorax·2018
Same author

Increased Platelet-Monocyte Interaction in Stable COPD in the Absence of Platelet Hyper-Reactivity.

Respiration; international review of thoracic diseases·2017
Same journal

[Insulin intoxications caused by falsified semaglutide].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Professional skepticism in medical research].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Improving mobility in painful osteoarthritis].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The effectiveness and costs of the Back At work After Surgery (BAAS) work-integrated care pathway on return to work for patients receiving knee arthroplasty].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The rise of genetic therapies: urgent moral and societal questions].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[A man with a wound on his elbow].

Nederlands tijdschrift voor geneeskunde·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Statins in COPD--theoretical reflections].

Jorien D C Hannink1, Yvonne F Heijdra

  • 1Universitair Medisch Centrum St Radboud, Afd. Longziekten, Nijmegen, the Netherlands. j.hannink@elg.umcn.nl

Nederlands Tijdschrift Voor Geneeskunde
|October 28, 2010
PubMed
Summary
This summary is machine-generated.

Statins may help manage chronic obstructive pulmonary disease (COPD) progression and its related cardiovascular issues due to their anti-inflammatory effects. However, current evidence is limited, and it is unclear if benefits stem from anti-inflammatory or cholesterol-lowering properties.

Related Experiment Videos

Last Updated: Jun 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Respiratory Medicine
  • Cardiology
  • Pharmacology

Context:

  • Systemic inflammation is implicated in the pathogenesis and extrapulmonary manifestations of Chronic Obstructive Pulmonary Disease (COPD), particularly cardiovascular disease.
  • Statins possess both cholesterol-lowering and anti-inflammatory properties, suggesting potential benefits beyond lipid management.

Purpose:

  • To explore the potential role of statins in preventing COPD progression and the development of its extrapulmonary manifestations.
  • To investigate whether statins' anti-inflammatory or cholesterol-lowering effects contribute to improved outcomes in COPD patients.

Summary:

  • Statins may positively influence lung function decline, exacerbation frequency, exercise tolerance, and mortality in COPD patients.
  • Evidence supporting these benefits is currently weak.
  • The precise mechanism (anti-inflammatory vs. cholesterol-lowering) underlying potential benefits in patients with or without unrecognized cardiovascular disease remains unclear.

Impact:

  • Findings could inform clinical practice regarding statin use in COPD management.
  • Highlights the need for further research to elucidate the mechanisms of statin action in COPD.
  • May guide the development of targeted therapies for COPD and its comorbidities.